Back to News
Market Impact: 0.15
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
BioNTech announced the first topline results from the AHEAD-MERIT Phase 2/3 trial (NCT04534205) of its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran, or tenu-ra). The provided article text does not state the results or their implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- Mainspring, AEP Strike Deal to Bring Power Online Faster
- Why this little known Chinese chipmaker has caused a global stock rout
- Applied Materials CEO on Doubling Revenue Thanks To AI